Han X, Yang X, Ye X, Liu Q, Huang G, Wang J, Li W, Zheng A, Ni Y, Men M
Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong Province, China.
Indian J Cancer. 2015 Dec;52 Suppl 2:e56-60. doi: 10.4103/0019-509X.172514.
We aimed to assess the clinical outcome of computed tomography (CT)-guided percutaneous microwave ablation (MWA) in patients 75 years of age and older with early stage peripheral nonsmall cell lung cancer (NSCLC).
Twenty-eight patients, aged ≥ 75 years, with Stage I and lymph node-negative IIa peripheral NSCLC underwent CT-guided percutaneous MWA in our hospital between July 2007 and March 2015. The overall 1-, 2-, 3-, and 4-year survival rates were estimated using Kaplan-Meier analysis. Adverse events were recorded.
The median follow-up time was 22.5 months. The overall median survival time (MST) was 35 months (95% confidence interval [CI] 22.3-47.7 months), and the cancer-specific MST was 41.9 months (95% CI 38.8-49.9 months). The 1-, 2-, 3-, and 4-year overall survival rates were 91.7%, 76.5%, 47.9%, and 47.9%, while the cancer-specific survival rates were 94.7%, 73.9%, 64.7%, and 64.7%, respectively. Median time to local progression was 28.0 months (95% CI 17.7-38.3 months). Major complications were included pneumothorax (21.4%, requiring drainage), pleural effusions (3.6%, requiring drainage), and pulmonary infection (3.6%).
CT-guided percutaneous MWA is safe and effective for the treatment of patients 75 years of age and older with medically inoperable early stage peripheral NSCLC.
我们旨在评估计算机断层扫描（CT）引导下经皮微波消融（MWA）治疗75岁及以上早期周围型非小细胞肺癌（NSCLC）患者的临床疗效。
2007年7月至2015年3月期间，我院对28例年龄≥75岁、I期且淋巴结阴性的IIa期周围型NSCLC患者进行了CT引导下经皮MWA治疗。采用Kaplan-Meier分析估计总体1年、2年、3年和4年生存率。记录不良事件。
中位随访时间为22.5个月。总体中位生存时间（MST）为35个月（95%置信区间[CI] 22.3 - 47.7个月），癌症特异性MST为41.9个月（95% CI 38.8 - 49.9个月）。1年、2年、3年和4年的总体生存率分别为91.7%、76.5%、47.9%和47.9%，而癌症特异性生存率分别为94.7%、73.9%、64.7%和64.7%。局部进展的中位时间为28.0个月（95% CI 17.7 - 38.3个月）。主要并发症包括气胸（21.4%，需要引流）、胸腔积液（3.6%，需要引流）和肺部感染（3.6%）。
CT引导下经皮MWA治疗75岁及以上医学上无法手术的早期周围型NSCLC患者是安全有效的。
